How new drug R&D can solve intractable scientific problems and meet clinical needs: insights from analysis of typical use cases

Abstract

New drug research and development (R&D) faces critical challenges such as drug resistance, ineffectiveness of single-target interventions, “undruggable” targets, long cycles, and high costs. This article analyzes five typical use cases to illustrate breakthrough strategies for addressing these issues. Innovations include the identification of dual-target antibiotics (paenimicin) and phospholipid-targeting antifungals (mandimycin) that overcome microbial resistance via mining silent biosynthetic gene clusters; development of “molecular glue” compounds (D927 and BBO-10203) that regulate protein-protein interactions, thus addressing insulin resistance and tumor drug resistance; AI-driven discovery of the TNIK inhibitor rentosertib for reversing pulmonary fibrosis; use of protein interface remodeling to develop the KRAS G12D inhibitor zoldonrasib for “undruggable” targets; and repurposing of existing drug combinations (letrozole plus irinotecan), on the basis of multi-omics data for Alzheimer’s disease. These use cases demonstrate how interdisciplinary technologies (e.g., AI and structural biology) and strategic innovations (multi-target design and drug repurposing) can drive a transformation from experience-driven to precision and intelligence-driven R&D, and provides a reference for meeting intractable clinical needs.

Keywords

new drug R&D / drug resistance / dual-target strategy / AI-driven R&D / undruggable targets / drug repurposing / protein-protein interactions

References

[1] He W, Huan X, Li Y, Deng Q, Chen T, Xiao W, et al.: A Broad-Spectrum Antibiotic Targets Multiple-Drug-Resistant Bacteria with Dual Binding Targets and no Detectable Resistance. Nature Communications 2025, 16: 7048.

[2] Deng Q, Li Y, He W, Chen T, Liu N, Ma L, et al.: A Polyene Macrolide Targeting Phospholipids in the Fungal Cell Membrane. Nature 2025, 640: 743-751.

[3] Simanshu DK, Xu R, Stice JP, Czyzyk DJ, Feng S, Denson JP, et al.: BBO-10203 Inhibits Tumor Growth Without Inducing Hyperglycemia by Blocking RAS-PI3Kα Interaction. Science 2025, 389: 409-415.

[4] Terayama K, Furuzono S, Fer N, Yan W, Young LC, Czyzyk DJ, et al.: Molecular Glues that Facilitate RAS Binding to PI3Kα Promote Glucose Uptake Without Insulin. Science 2025, 389: 402-408.

[5] Xu Z, Ren F, Wang P, Cao J, Tan C, Ma D, et al.: A Generative AI-Discovered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis: A Randomized Phase 2a Trial. Nature Medicine 2025, 31: 2602-2610.

[6] Weller C, Burnett GL, Jiang L, Chakraborty S, Zhang D, Vita NA, et al.: A Neomorphic Protein Interface Catalyzes Covalent Inhibition of RAS^G12D Aspartic Acid in Tumors . Science 2025, 389: eads0239.

[7] Li Y, Pereda Serras C, Blumenfeld J, Xie M, Hao Y, Deng E, et al.: Cell-Type-Directed Network-Correcting Combination Therapy for Alzheimer’s Disease. Cell 2025, 188: 5516-5534.e18.